Lupin

Who are the top shareholders of the Lupin?

The top shareholders of Lupin include Lupin Investments Pvt Ltd with 45.38%, institutional investors with 38 mutual fund schemes holding 17.55% and 872 foreign institutional investors holding 21.46%, and HDFC Trustee Company Ltd as the highest public shareholder at 3.22%. Individual investors account for 5.1% of the holdings.

The top shareholders of Lupin include the promoters, with Lupin Investments Pvt Ltd holding the largest stake at 45.38%. Additionally, institutional investors play a significant role, with 38 mutual fund schemes collectively holding 17.55% and 872 foreign institutional investors (FIIs) holding 21.46%. The highest public shareholder is HDFC Trustee Company Ltd through the HDFC Balanced Advantage Fund, which holds 3.22%. Individual investors account for 5.1% of the holdings.

how big is Lupin?

As of Jun 06, Lupin Ltd. has a market capitalization of 91,339.09 Cr, with recent net sales of 22,707.90 Cr and a net profit of 3,281.62 Cr over the last four quarters.

Market Cap: Lupin Ltd. has a market capitalization of 91,339.09 Cr and is classified as a Large Cap company as of Jun 06.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes data from Mar'25, Dec'24, Sep'24, and Jun'24, is 22,707.90 Cr. The sum of Net Profit for the same period is 3,281.62 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 14,290.29 Cr, while Total Assets amount to 23,694.65 Cr.

What is the bonus history of the Lupin?

Lupin Ltd. announced a 1:1 bonus issue on August 11, 2006, with a record date of August 14, 2006, allowing shareholders to receive an additional share for each share owned.

Lupin Ltd. has a bonus history that includes a notable 1:1 bonus issue announced on August 11, 2006. The record date for this bonus was August 14, 2006. This means that shareholders on record as of that date received an additional share for each share they owned.

Has Lupin declared dividend?

Yes, Lupin Ltd. has declared a 400% dividend, amounting to ₹8 per share, with an ex-date of July 16, 2024. Despite a recent 6.04% decline in the last 6 months, the company has shown strong total returns over longer periods, particularly a 234.26% return over the past 3 years.

Lupin Ltd. has declared a 400% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 400%<BR>- Amount per share: 8<BR>- Ex-date: 16 Jul 24<BR><BR>Dividend Yield: 0.4%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -6.04%, with a dividend return of 0%, resulting in a total return of -6.04%.<BR><BR>Over the past year, the price return was 24.64%, the dividend return was 0.50%, leading to a total return of 25.14%.<BR><BR>In the 2-year period, the price return reached 143.95%, with a dividend return of 1.45%, culminating in a total return of 145.4%.<BR><BR>For the last 3 years, the price return was 231.65%, the dividend return was 2.61%, resulting in a total return of 234.26%.<BR><BR>Over the past 4 years, the price return stood at 62.73%, with a dividend return of 1.93%, leading to a total return of 64.66%.<BR><BR>In the 5-year period, the price return was 122.08%, the dividend return was 3.18%, resulting in a total return of 125.26%.<BR><BR>Overall, Lupin Ltd. has declared a substantial dividend, and the total returns over various periods indicate a generally positive performance, particularly in the longer-term horizons, despite a recent decline in the short term.

Who are the peers of the Lupin?

Lupin's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Aurobindo Pharma, Abbott India, Alkem Lab, Glaxosmi. Pharma, and Glenmark Pharma. In terms of management risk, growth, and capital structure, Lupin is rated average, with a 1-year return of 23.25%, higher than Aurobindo Pharma but lower than Divi's Lab at 51.96%.

Peers: The peers of Lupin are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Aurobindo Pharma, Abbott India, Alkem Lab, Glaxosmi. Pharma, and Glenmark Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Abbott India, and Glaxosmi. Pharma, while Good management risk is found at Divi's Lab., Torrent Pharma, Aurobindo Pharma, Alkem Lab, and Glenmark Pharma. Average management risk is noted for Lupin. In terms of Growth, Excellent growth is seen at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Lupin, while Below Average growth is noted for Divi's Lab., Torrent Pharma, Aurobindo Pharma, Alkem Lab, and Glaxosmi. Pharma. Excellent capital structure is present in Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Aurobindo Pharma, Abbott India, Alkem Lab, and Glaxosmi. Pharma, while Good capital structure is found at Torrent Pharma and Lupin.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while Aurobindo Pharma has the lowest at -6.51%. Lupin's own 1-year return of 23.25% is higher than Aurobindo Pharma's but lower than Divi's Lab.'s. Additionally, the peers with negative six-month returns include Aurobindo Pharma, Alkem Lab, and Lupin.

Who are in the management team of Lupin?

As of March 2023, the management team of Lupin includes M D Gupta (Chairman), Nilesh Deshbandhu Gupta (Managing Director), Vinita Gupta (CEO), R V Satam (Company Secretary), and several independent directors including Jean-Luc Belingard, Mark D McDade, K B S Anand, and Punita Kumar Sinha, along with Ramesh Swaminathan (CFO). They collectively oversee the company's operations and strategic direction.

As of March 2023, the management team of Lupin includes the following individuals:<BR><BR>1. M D Gupta - Chairman (Non-Executive)<BR>2. Nilesh Deshbandhu Gupta - Managing Director<BR>3. Vinita Gupta - Director & Chief Executive Officer<BR>4. R V Satam - Company Secretary & Compliance Officer<BR>5. Jean-Luc Belingard - Independent Director<BR>6. Ramesh Swaminathan - Executive Director & Chief Financial Officer<BR>7. Mark D McDade - Independent Director<BR>8. K B S Anand - Independent Director<BR>9. Punita Kumar Sinha - Independent Director<BR><BR>These members play various roles in guiding and overseeing the company's operations and strategic direction.

What does Lupin do?

Lupin Ltd. is a global pharmaceutical company that develops and markets branded and generic drugs, biotechnology products, and active pharmaceutical ingredients. As of March 2025, it reported net sales of ₹56,671 Cr and a net profit of ₹7,725 Cr, with a market cap of ₹88,831 Cr.

Overview: <BR>Lupin Ltd. is an innovation-led transnational pharmaceutical company producing, developing, and marketing a wide range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally, operating within the Pharmaceuticals & Biotechnology industry and classified as a Large Cap company.<BR><BR>History: <BR>Lupin was incorporated in the year 1968. The latest quarterly results reported are for March 2025, showcasing the company's performance in terms of sales and profits.<BR><BR>Financial Snapshot: <BR>Net Sales: 56,671 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 7,725 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 88,831 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 27.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.41% <BR>Debt Equity: 0.07 <BR>Return on Equity: 19.08% <BR>Price to Book: 5.19 <BR><BR>Contact Details: <BR>Address: Kalpataru Inspire 3rd Floor, Off Western Exp HW Santacruz-E Mumbai Maharashtra : 400055 <BR>Tel: 91-22-6640 2323 <BR>Email: info@lupin.com <BR>Website: http://www.lupin.com

Is Lupin overvalued or undervalued?

As of November 7, 2025, Lupin is considered fairly valued with a PE ratio of 20.82, an attractive valuation compared to peers like Sun Pharma and Divi's Lab, despite a year-to-date return of -16.17%, supported by strong ROCE and ROE metrics.

As of 7 November 2025, Lupin's valuation grade has moved from very attractive to attractive. The company is currently considered fairly valued. Key ratios include a PE ratio of 20.82, an EV to EBITDA of 13.53, and a PEG ratio of 0.32, indicating strong growth potential relative to its price. <BR><BR>In comparison to its peers, Lupin's valuation appears more favorable; for instance, Sun Pharma has a PE ratio of 35.17 and Divi's Lab stands at 71.11, both categorized as expensive. Other attractive peers include Cipla with a PE of 22.33 and Dr. Reddy's Labs at 17.43. Despite a challenging year-to-date return of -16.17% compared to the Sensex's 6.50%, Lupin's solid ROCE of 22.16% and ROE of 19.08% suggest it remains a robust investment in the pharmaceuticals sector.

How has been the historical performance of Lupin?

Lupin has shown significant growth in net sales and profitability from March 2019 to March 2025, with net sales increasing from 14,664.56 Cr to 22,707.90 Cr and profit after tax rising from 517.27 Cr to 3,306.26 Cr, indicating strong operational efficiency and recovery. Total assets and liabilities also grew, reflecting balanced financial health.

Answer:<BR>The historical performance of Lupin shows a significant upward trend in net sales and profitability over the past few years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Lupin's net sales have steadily increased from 14,664.56 Cr in March 2019 to 22,707.90 Cr in March 2025, reflecting a robust growth trajectory. Total operating income followed a similar pattern, rising from 14,664.56 Cr in March 2019 to 22,707.90 Cr in March 2025. The total expenditure, excluding depreciation, also grew from 12,103.84 Cr in March 2019 to 17,424.59 Cr in March 2025, indicating increased operational costs alongside revenue growth. Operating profit (PBDIT) saw a remarkable rise from 2,560.72 Cr in March 2019 to 5,479.13 Cr in March 2025, showcasing improved operational efficiency. Profit before tax surged from 1,405.21 Cr in March 2019 to 4,015.00 Cr in March 2025, while profit after tax increased from 517.27 Cr to 3,306.26 Cr during the same period. The consolidated net profit also reflected this positive trend, climbing from 606.55 Cr in March 2019 to 3,281.62 Cr in March 2025. Additionally, the company's total assets rose from 24,809.54 Cr in March 2020 to 28,645.78 Cr in March 2025, while total liabilities increased from 24,809.54 Cr to 28,645.78 Cr, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities improved significantly, reaching 2,999.00 Cr in March 2025, despite a negative cash flow from investing activities of -4,171.00 Cr, which suggests substantial investments in growth initiatives. Overall, Lupin's financial performance demonstrates a strong recovery and growth phase, particularly in the last fiscal year.

Is Lupin technically bullish or bearish?

As of November 28, 2025, Lupin's technical trend has shifted to bullish, supported by strong indicators such as a bullish MACD, Bollinger Bands, and moving averages, along with a recent price action that exceeds the previous close.

As of 28 November 2025, the technical trend for Lupin has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish. Daily moving averages also indicate a bullish trend. The KST shows a bullish signal on the weekly timeframe, while the Dow Theory reflects a mildly bullish stance on both weekly and monthly timeframes. The OBV is mildly bullish on the weekly and bullish on the monthly. Overall, the strength of the bullish trend is reinforced by the recent price action, with today's high surpassing the previous close.

When is the next results date for Lupin Ltd.?

The next results date for Lupin Ltd. is 12 February 2026.

The next results date for Lupin Ltd. is scheduled for 12 February 2026.

Are Lupin Ltd. latest results good or bad?

Lupin Ltd.'s latest results show strong revenue growth with record net sales of ₹7,167.52 crores, up 24.27% year-on-year, but profitability has declined, with net profit down 20.46% sequentially and operating margins contracting. Investors should be cautious due to these mixed signals regarding sustainability.

Lupin Ltd.'s latest results present a mixed picture. On one hand, the company achieved record net sales of ₹7,167.52 crores in Q3 FY26, reflecting a significant year-on-year growth of 24.27% and a modest quarter-on-quarter increase of 1.70%. This indicates strong revenue momentum, particularly in the US generics and specialty segments.<BR><BR>However, the results also show a concerning decline in profitability. The net profit for the quarter fell by 20.46% sequentially to ₹1,175.55 crores, despite a year-on-year increase of 37.47%. Additionally, the operating profit margin contracted to 31.86% from 34.27% in the previous quarter, and the PAT margin decreased to 16.63% from 21.74%. This margin compression raises questions about the sustainability of profitability, particularly given rising interest costs and potential pricing pressures.<BR><BR>Overall, while the revenue growth is commendable, the decline in profits and margins suggests that investors should approach the results with caution, monitoring future quarters for signs of recovery in profitability.

Should I buy, sell or hold Lupin Ltd.?

Why is Lupin Ltd. falling/rising?

As of 17-Mar, Lupin Ltd.'s stock price is rising to 2,297.00, indicating a potential recovery in investor sentiment after recent declines. Despite a drop in delivery volume, the stock remains liquid, supported by strong financial health and high institutional holdings, contributing to its positive outlook.

As of 17-Mar, Lupin Ltd.'s stock price is rising, currently at 2,297.00, reflecting a change of 6.85 (0.3%) upward. This increase follows a trend reversal after two consecutive days of decline, indicating a potential recovery in investor sentiment. The stock's performance today is in line with its sector, and it is close to its 52-week high, being only 3.44% away from the high of Rs 2,376.<BR><BR>Despite a recent drop in investor participation, with delivery volume falling by 44.09% against the 5-day average, the stock remains liquid enough for trading, suggesting that there is still interest among investors. The company has demonstrated strong financial health, with a low Debt to Equity ratio of 0.10 times and consistent growth in net sales and operating profit. Over the past year, the stock has generated a return of 15.60%, while profits have risen significantly by 73.5%, contributing to its attractive valuation.<BR><BR>Additionally, high institutional holdings at 47.08% indicate confidence from larger investors who typically have more resources to analyze company fundamentals. The company has also been rated highly by MarketsMojo, ranking in the top 1% across a large pool of stocks, which further supports its positive outlook. Overall, these factors contribute to the stock's upward movement, reflecting a combination of strong financial performance and investor confidence.

Why is Lupin Ltd. falling/rising?

As of 18-Mar, Lupin Ltd.'s stock price is 2,295.00, down 0.14%. The decline is due to underperformance compared to the benchmark and sector, along with decreased investor participation, despite strong long-term growth indicators.

As of 18-Mar, Lupin Ltd.'s stock price is currently at 2,295.00, reflecting a decrease of 3.25 points or 0.14%. This decline can be attributed to several factors highlighted in the recent performance data. Over the past week, the stock has underperformed, showing a decrease of 2.15%, while the benchmark Sensex only fell by 0.21%. Additionally, the stock's performance today has underperformed its sector by 0.41%.<BR><BR>Investor participation appears to be declining, as evidenced by a significant drop in delivery volume, which fell by 15.76% compared to the 5-day average. This reduction in trading activity may indicate waning interest among investors, contributing to the stock's downward movement.<BR><BR>Despite these negative indicators, it is important to note that Lupin Ltd. has shown strong long-term growth, with net sales increasing at an annual rate of 11.42% and operating profit growing at 33.60%. The company has also reported positive results for the last three consecutive quarters, with a notable increase in profits. However, the current market sentiment and the recent underperformance relative to both the sector and the benchmark may be influencing the stock's price decline at this time.

Why is Lupin Ltd. falling/rising?

As of 19-Mar, Lupin Ltd.'s stock price is declining, currently at 2,261.00, reflecting a decrease of 1.8%. Despite strong fundamentals, the stock has underperformed the market and is experiencing negative sentiment, influenced by sector performance and recent price trends.

As of 19-Mar, Lupin Ltd.'s stock price is falling, currently at 2,261.00, which reflects a decrease of 41.55 (-1.8%). This decline follows a trend reversal after two consecutive days of gains. The stock has underperformed the broader market, with a 1-week performance of -4.07% compared to the Sensex's -2.40%. <BR><BR>Today's trading session saw the stock touch an intraday low of Rs 2,242, marking a drop of 2.63%. Additionally, the Pharmaceuticals & Drugs sector has also experienced a decline of -2.13%, which may be contributing to the downward pressure on Lupin's stock price. Despite a rise in investor participation, with delivery volume increasing by 78.58% against the 5-day average, the overall sentiment appears to be negative.<BR><BR>While the company has demonstrated strong fundamentals, including a low debt-to-equity ratio and consistent growth in net sales and operating profit, these positive factors have not been sufficient to counteract the recent price drop. The stock is still trading above its 50-day, 100-day, and 200-day moving averages, but it is below its 5-day and 20-day moving averages, indicating a short-term weakness. Overall, the combination of sector performance, recent price action, and market sentiment has led to the current decline in Lupin Ltd.'s stock price.

Why is Lupin Ltd. falling/rising?

As of 20-Mar, Lupin Ltd. is seeing its stock price rise to Rs 2,322.45, up 3.04%, driven by strong performance metrics and positive financial results. The stock has outperformed the Sensex and is trading near its 52-week high, supported by low debt and high institutional holdings.

As of 20-Mar, Lupin Ltd. is experiencing a rise in its stock price, currently at Rs 2,322.45, reflecting an increase of Rs 68.55 or 3.04%. This upward movement can be attributed to several positive factors. The stock has outperformed the Sensex, showing a gain of 0.33% over the past week while the benchmark has slightly declined by 0.04%. Over the past month, Lupin's stock has risen by 4.63%, contrasting sharply with the Sensex's drop of 10.00%. Year-to-date, the stock has increased by 9.96%, while the Sensex has fallen by 12.54%.<BR><BR>Additionally, the stock is trading close to its 52-week high, just 2.31% away from Rs 2,376. The performance today has also been strong, with the stock reaching an intraday high of Rs 2,338.2, marking a 3.74% increase. Furthermore, Lupin is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bullish trend.<BR><BR>The company's fundamentals support this rise, with a low debt-to-equity ratio of 0.10 times and healthy long-term growth rates in net sales and operating profit. The positive financial results over the last three quarters, including a significant growth in profit after tax and net sales, further bolster investor confidence. With a return on equity (ROE) of 22 and a price-to-book value of 5.4, the stock is considered attractively valued compared to its peers.<BR><BR>Moreover, high institutional holdings at 47.08% suggest that knowledgeable investors are backing the stock, which can positively influence its price. Overall, the combination of strong performance metrics, positive financial results, and favorable market conditions contributes to the rising stock price of Lupin Ltd.

Why is Lupin Ltd. falling/rising?

As of 23-Mar, Lupin Ltd.'s stock price is at 2,285.00, down 1.61%, despite outperforming its sector today. The stock has shown volatility with a 0.22% decline over the past week but an 8.19% increase year-to-date, supported by strong financial health and consistent profit growth, although it is currently trading below its moving averages.

As of 23-Mar, Lupin Ltd.'s stock price is falling, currently at 2,285.00, reflecting a decrease of 37.45 or 1.61%. This decline occurs despite the stock outperforming its sector by 1.96% today, as the broader Pharmaceuticals & Drugs sector has fallen by 3.58%. <BR><BR>In terms of recent performance, the stock has shown a modest decline of 0.22% over the past week, while it has increased by 1.78% over the past month, indicating some volatility. Year-to-date, the stock has performed well, with an increase of 8.19%, contrasting with a significant drop of 14.70% in the Sensex. <BR><BR>Despite the current price drop, there are several positive indicators for Lupin Ltd. The company has demonstrated strong financial health, with a low debt-to-equity ratio of 0.10 times and consistent growth in net sales and operating profit. Additionally, it has reported positive results for the last three consecutive quarters, with a notable increase in profits. <BR><BR>However, the stock is currently trading lower than its 5-day and 20-day moving averages, which may contribute to the downward pressure on its price. The stock is also 3.98% away from its 52-week high, suggesting that while it has potential for recovery, the recent performance has not been sufficient to maintain upward momentum. <BR><BR>Overall, while there are strong fundamentals supporting Lupin Ltd., the current market conditions and sector performance appear to be influencing the stock's decline.

Why is Lupin Ltd. falling/rising?

As of 24-Mar, Lupin Ltd.'s stock price is rising to 2,331.75, up 1.5%, driven by strong financial performance, increased investor confidence, and positive market sentiment, while outperforming the declining Sensex. The stock is close to its 52-week high and shows robust trading activity and institutional support.

As of 24-Mar, Lupin Ltd.'s stock price is rising, currently at 2,331.75, reflecting a change of 34.55 (1.5%) upward. This increase can be attributed to several positive factors. The stock has outperformed the benchmark Sensex, which has declined by 2.63% over the past week, while Lupin has seen a gain of 1.46%. Over the past month, Lupin's stock has risen by 3.58%, contrasting with a 9.92% drop in the Sensex.<BR><BR>Additionally, Lupin is trading close to its 52-week high, just 1.9% away from Rs 2,376, and it reached an intraday high of Rs 2,349, which is a 2.25% increase for the day. The stock is also performing well in terms of moving averages, trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend.<BR><BR>Investor participation has increased significantly, with a delivery volume of 7.6 lacs on 23 March, which is up by 58.87% compared to the 5-day average. This rise in trading activity suggests growing confidence among investors. Furthermore, the company has demonstrated strong financial performance, with net sales growing at an annual rate of 11.42% and operating profit increasing by 33.60%. The positive results over the last three consecutive quarters, along with a low debt-to-equity ratio of 0.10, contribute to the stock's attractiveness.<BR><BR>Lupin's high institutional holdings at 47.08% indicate that knowledgeable investors are backing the stock, further supporting its upward movement. Overall, the combination of strong financial metrics, positive market sentiment, and increased trading activity are key reasons for the rise in Lupin Ltd.'s stock price.

Why is Lupin Ltd. falling/rising?

As of 25-Mar, Lupin Ltd. is seeing a stock price increase to 2,347.45, driven by strong performance metrics, positive financial results, and growing investor confidence. The stock has outperformed the benchmark Sensex and shows a bullish trend with significant returns over various periods.

As of 25-Mar, Lupin Ltd. is experiencing a rise in its stock price, currently at 2,347.45, with an increase of 15.7 (0.67%). This upward movement can be attributed to several positive factors. The stock has shown a consistent performance, gaining 2.19% over the last two days and outperforming the benchmark Sensex, which has declined by 1.87% over the past week. <BR><BR>Furthermore, Lupin's stock has demonstrated strong returns over various periods, including an impressive 11.15% increase year-to-date and a substantial 266.93% rise over the last three years. The company has also reported positive financial results in the last three consecutive quarters, with net sales reaching Rs 7,167.52 crore and a significant growth in profit before tax. <BR><BR>Additionally, the stock is trading above its moving averages, indicating a bullish trend. The rising investor participation, evidenced by a 46.78% increase in delivery volume, suggests growing confidence among investors. With a low debt-to-equity ratio and attractive valuations compared to its peers, Lupin Ltd. is positioned favorably in the market, contributing to its rising stock price.

Which are the latest news on Lupin?